CASCADIAN THERAPEUTICS, INC. (NASDAQ:CASC) Files An 8-K Results of Operations and Financial Condition

CASCADIAN THERAPEUTICS, INC. (NASDAQ:CASC) Files An 8-K Results of Operations and Financial Condition

Story continues below

Item2.02 Results of Operations and Financial Condition

On May9, 2017, Cascadian Therapeutics, Inc. (the Company) issued
a press release and will hold a conference call regarding the
Companys financial results for the quarter ended March31, 2017
and providing a corporate update. A copy of the Companys press
release is furnished herewith as Exhibit 99.1 and incorporated
herein by reference.

The information in this report, including Exhibit 99.1, is being
furnished and shall not be deemed filed for purposes of Section18
of the Securities Exchange Act of 1934, as amended, or otherwise
subject to the liabilities of that section or Sections 11 and
12(a)(2) of the Securities Act of 1933, as amended, nor shall it
be incorporated by reference into any other filing with the U.S.
Securities and Exchange Commission, whether made before, on or
after the date hereof, regardless of any general incorporation
language in such filing, except as expressly set forth by
specific reference in such filing.

Item9.01 Financial Statements and Exhibits

(d) Exhibits.




99.1 Press Release issued by Cascadian Therapeutics, Inc. dated
May 9, 2017.



Cascadian Therapeutics, Inc., formerly Oncothyreon Inc., is a clinical-stage biopharmaceutical company. The Company focuses on the development of therapeutic products for the treatment of cancer. The Company’s clinical-stage product candidate includes ONT-380, an orally active and selective small-molecule human epidermal growth factor receptor (HER) 2 inhibitor. The Company’s ONT-10 is a therapeutic vaccine targeting the Mucin 1 peptide antigen (MUC1). The Company is engaged in developing preclinical product candidates in oncology using its Checkpoint kinase 1 (Chk1) kinase inhibitor and protocell technology. The Company completed the evaluation of approximately two dosing cohorts in its Phase Ib trial of ONT-10 in combination with the anti-CD27 T-cell agonist antibody varlilumab in collaboration with other company. The Company has completed Phase I trial of ONT-380, with both dose-escalation and expansion components. The Company has initiated Phase Ib trials of ONT-380.


CASCADIAN THERAPEUTICS, INC. (NASDAQ:CASC) closed its last trading session down -0.07 at 4.06 with 91,293 shares trading hands.

An ad to help with our costs